Hims LegitScript and Accreditation Status: Is Hims a Legitimate Telehealth Provider?

What Is LegitScript Certification and Does Hims Have It?

LegitScript is a third-party verification company that certifies online pharmacies and telehealth platforms against standards aligned with the National Association of Boards of Pharmacy (NABP) and applicable federal law. Hims holds active LegitScript certification in the online pharmacy category, which means its pharmacy operations passed LegitScript's review of licensure, prescribing practices, and dispensing protocols at the time of certification.

LegitScript certification is not a federal government credential. It is a private-sector compliance signal used by payment networks (Visa, Mastercard, Google Ads) to approve pharmacy-related advertising. The FDA, DEA, and state pharmacy boards remain the authoritative licensing bodies.

What LegitScript Certification Actually Covers

LegitScript reviews whether a pharmacy (1) dispenses only via valid prescriptions, (2) holds valid state licenses in jurisdictions where it operates, (3) sells only FDA-approved or lawfully compounded drugs, and (4) does not dispense controlled substances without a legitimate patient-provider relationship. Passing these checks earns the "Certified" badge.

LegitScript does not audit clinical quality, evaluate prescriber competence, or assess whether a telehealth consultation is medically thorough. A platform can be LegitScript-certified and still receive patient complaints about care quality.

How to Verify Hims's Current Status

You can verify Hims's certification directly at LegitScript's public database. Certification statuses change. If Hims were to lose certification, Google and major payment networks would be notified automatically. As of the last editorial review date of this article, Hims held active certification.

FDA Oversight and Enforcement Actions Against Hims

The FDA regulates drug marketing, compounding practices, and the distribution of prescription medications through telehealth channels. Hims has attracted FDA scrutiny specifically around its compounded GLP-1 products.

The March 2025 FDA Warning Letter

In March 2025, the FDA issued a warning letter to Hims related to the marketing of compounded semaglutide products. The FDA's core objection was that Hims was promoting compounded semaglutide as equivalent to FDA-approved Ozempic (semaglutide injection, Novo Nordisk) and Wegovy (semaglutide 2.4 mg, Novo Nordisk) after the agency had determined that the semaglutide shortage on the FDA Drug Shortages Database had been resolved. Under 503A and 503B compounding rules, a drug listed on the shortage list may be compounded by licensed pharmacies; once removed from the shortage list, that exemption disappears for most compounders. The full text of FDA warning letters is publicly available at accessdata.fda.gov.

Hims publicly disputed the FDA's shortage-resolution determination and argued that supply chain gaps persisted for patients. That public dispute did not change the regulatory outcome. The FDA's position under 21 U.S.C. 503A and 503B is that compounders may not copy FDA-approved drugs unless a shortage exists on the official shortage database.

FDA-Approved Drugs Hims Does Prescribe Legitimately

Hims prescribes and dispenses several FDA-approved medications through standard pharmacy channels. These include sildenafil (generic Viagra, approved 1998) and tadalafil (generic Cialis, approved 2003) for erectile dysfunction, finasteride 1 mg (generic Propecia, approved 1997) for androgenetic alopecia, and minoxidil topical solution for hair loss. The FDA's prescribing information for sildenafil is available at accessdata.fda.gov.

Prescribing these drugs via telehealth is legal provided a valid patient-provider relationship exists, a legitimate medical evaluation is conducted, and applicable state telehealth laws are met. The Ryan Haight Online Pharmacy Consumer Protection Act (21 U.S.C. 829) requires at least one in-person or telemedicine evaluation before controlled substance prescriptions are issued. Sildenafil and finasteride are not controlled substances, so Ryan Haight does not apply to them directly, though state-specific telehealth prescribing rules still govern.

BBB Rating, Consumer Complaints, and Billing Practices

The Better Business Bureau (BBB) assigns Hims an A rating as of mid-2025, based primarily on responsiveness to complaints rather than complaint volume. Hims is not BBB Accredited, meaning the company has not paid for BBB accreditation membership. An A rating without accreditation indicates the company responds to complaints logged through the BBB system but has not undergone proactive BBB review.

Volume and Themes of Consumer Complaints

The BBB complaint database for Hims shows several hundred complaints over the trailing 36-month window, which is expected for a company processing millions of subscriptions annually. Complaint themes cluster around three areas:

• Auto-renewal billing without perceived adequate notice
• Difficulty canceling subscriptions through the app or website
• Delays in prescription fulfillment or shipping without proactive communication

These complaint patterns are consistent with what the Consumer Financial Protection Bureau (CFPB) tracks for subscription commerce broadly. The CFPB's complaint database at consumerfinance.gov contains entries referencing Hims billing practices. High complaint volume relative to transaction volume is the metric that matters. Hims processes an estimated 1 million-plus active subscriptions; a few hundred BBB complaints per year represents a complaint rate well below 0.1% of active users, though each individual complaint reflects a real patient experience.

Steps Patients Report Using to Cancel

Patients who have documented successful cancellation typically describe navigating to account settings inside the Hims app, selecting the specific subscription (each product line is a separate subscription), and completing a multi-step confirmation. Hims's terms of service require cancellation before the next billing cycle to avoid a charge. The FTC's Negative Option Rule, updated in 2023 and effective 2024, requires that subscription cancellation be at least as easy as sign-up. Whether Hims's current flow meets that standard has not been adjudicated publicly as of this article's review date. The updated FTC Negative Option Rule is available at ftc.gov.

State Medical Board and Pharmacy Board Licensing

Hims employs or contracts with licensed physicians, nurse practitioners, and physician assistants in all 50 states. Each prescriber holds state-specific licensure. State medical boards regulate those prescribers individually, not Hims as a corporate entity. If a prescriber employed by Hims were to face disciplinary action, that action would appear on the relevant state board's public license lookup, not on any centralized Hims record.

How to Check Prescriber Credentials

Patients can verify individual prescriber licensure through the Federation of State Medical Boards (FSMB) DocInfo tool at fsmb.org. This lookup covers all U.S. States and the District of Columbia. For nurse practitioners and physician assistants, state-specific nursing or PA board websites are the verification source.

Pharmacy Licensing

Hims dispenses through pharmacies that must hold valid state pharmacy licenses in every state where they ship. The NABP's Drug Distributor Accreditation and Pharmacy Verification programs at nabp.pharmacy provide a secondary check on whether a pharmacy partner holds good standing. Patients can also verify pharmacy licensure directly with the state board of pharmacy in their state of residence.

Clinical Standards: What the Prescribing Process Actually Looks Like

Hims uses a combination of asynchronous questionnaire-based consultations and synchronous video visits. For lower-risk medications like sildenafil or finasteride, the standard path is an asynchronous questionnaire reviewed by a licensed provider who issues a prescription without a real-time video call. For higher-risk products or controlled substances (rare in Hims's catalog), synchronous visits are required.

Asynchronous Prescribing: Legitimate or a Rubber Stamp?

Asynchronous telehealth prescribing is legal under federal law and most state telehealth statutes, provided the questionnaire captures adequate clinical information for the prescribing decision. The American Telemedicine Association (ATA) has published clinical practice guidelines supporting asynchronous care for specific low-acuity conditions. Those guidelines are available at americantelemed.org.

The clinical concern is whether a questionnaire reliably identifies contraindications. For sildenafil, the key contraindication is concurrent nitrate therapy (e.g., nitroglycerin), which carries an absolute contraindication due to risk of severe hypotension. Hims's intake questionnaire asks about nitrate use. Whether every patient answers accurately is a patient-side limitation, not necessarily a platform failure.

Finasteride carries a boxed warning for use in women of childbearing potential and is teratogenic to male fetuses. Hims prescribes finasteride only to adult men and screens for relevant contraindications in the intake form. The FDA prescribing information for finasteride 1 mg lists these warnings in detail at accessdata.fda.gov.

GLP-1 and Weight Loss Products

Hims began offering compounded semaglutide in 2023, when the drug appeared on the FDA Drug Shortages Database. The clinical data supporting semaglutide's efficacy is substantial. In the STEP-1 trial (N=1,961), subcutaneous semaglutide 2.4 mg once weekly produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [1]. In STEP-3 (N=611), combining semaglutide 2.4 mg with intensive behavioral therapy produced 16.0% mean weight loss at 68 weeks [2].

The clinical data for semaglutide applies to the FDA-approved formulation manufactured by Novo Nordisk under strict quality controls. Compounded semaglutide from a 503A pharmacy is not required to demonstrate bioequivalence to the branded product. The FDA has stated explicitly that compounded drugs are not FDA-approved and that patients and providers cannot assume they have the same safety, efficacy, or quality as approved drugs. The FDA's compounding FAQ is available at fda.gov.

The table below offers an independent framework for evaluating any telehealth platform's legitimacy before subscribing. This framework was developed by the HealthRX medical team based on publicly available regulatory criteria.

| Checkpoint | Where to Verify | Hims Status (July 2025) | |---|---|---| | LegitScript certification | legitscript.com | Active | | NABP pharmacy accreditation | nabp.pharmacy | Verify per pharmacy partner | | BBB rating | bbb.org | A (not Accredited) | | FDA warning letters | accessdata.fda.gov | 1 letter (March 2025, compounded semaglutide) | | State medical board complaints | fsmb.org | Individual prescribers, not entity | | FTC compliance (subscription cancellation) | ftc.gov | Not formally adjudicated |

Testosterone and Men's HRT: What Hims Offers and What It Doesn't

Hims offers products marketed for testosterone support, primarily oral supplements and topical over-the-counter products, rather than prescription testosterone replacement therapy (TRT) in most states. This is an area where patients frequently conflate supplement marketing with clinical TRT.

The Distinction Between Supplement-Based "T-Support" and Prescription TRT

Prescription testosterone (testosterone cypionate injection, testosterone enanthate injection, topical gels like AndroGel) is a Schedule III controlled substance under the DEA. Prescribing it via pure asynchronous telehealth without a synchronous evaluation and laboratory confirmation of low serum testosterone is inconsistent with Endocrine Society Clinical Practice Guidelines, which recommend confirming low testosterone on at least two morning serum samples before initiating therapy [3]. The Endocrine Society guideline statement reads: "We recommend against starting testosterone therapy in patients without a confirmed diagnosis of hypogonadism based on both clinical features and biochemical evidence" [3].

Hims's standard offering for most patients does not include prescription injectable or gel testosterone. Patients seeking true TRT through Hims should confirm in writing what product is being prescribed, verify the prescriber is licensed in their state, and obtain copies of any lab results used to justify the prescription.

Hair Loss: Finasteride Evidence Base

For androgenetic alopecia, finasteride 1 mg daily has the strongest evidence base among oral options. A 2-year placebo-controlled trial (N=1,553) showed that finasteride 1 mg increased hair count by 107 hairs in a defined scalp area versus a loss of 50 hairs with placebo at 24 months [4]. Hims prescribes finasteride 1 mg through its standard asynchronous flow, which is appropriate for this indication given the medication's established safety profile in men.

Post-finasteride syndrome (persistent sexual, neurological, and psychological adverse effects after discontinuation) remains a contested clinical topic. The FDA updated finasteride labeling in 2022 to include warnings about persistent side effects. Patients with a history of depression or sexual dysfunction should discuss those risk factors with a provider before starting finasteride. The updated label is at accessdata.fda.gov.

Mental Health Services: Scope and Limitations

Hims offers psychiatric medication management, primarily for anxiety and depression, through its platform. Selective serotonin reuptake inhibitors (SSRIs) such as sertraline and escitalopram are available via asynchronous or synchronous telehealth consultation.

The American Psychiatric Association's 2023 telepsychiatry practice guidelines support telehealth delivery of psychiatric services when appropriate patient selection criteria are met [5]. These criteria include stable, non-crisis presentations and exclusion of patients with recent suicidal ideation or active psychosis. Hims's intake screening asks about suicidal ideation as a safety screen.

SSRIs carry a black box warning for increased suicidality in patients under age 25. The FDA requires this warning across all SSRI labeling; the class labeling document is available at accessdata.fda.gov. Patients under 25 starting an SSRI through any platform should have a clear follow-up plan established before the first prescription is filled.

How Hims Compares to NABP-Accredited Pharmacy Standards

The NABP's Verified Internet Pharmacy Practice Sites (VIPPS) accreditation is widely considered the gold standard for online pharmacy legitimacy in the United States. VIPPS-accredited pharmacies have undergone on-site inspection and must meet ongoing compliance standards. The NABP's accredited pharmacy list is publicly searchable at nabp.pharmacy.

LegitScript certification, which Hims holds, is a separate and generally less rigorous standard than NABP VIPPS. That does not make LegitScript-certified platforms illegitimate. It means the level of independent verification is lower. Patients with specific concerns about a dispensing pharmacy can request the pharmacy's state license number and verify it directly with the relevant state board of pharmacy.

What Independent Clinicians and Guidelines Say

The American Urological Association (AUA) and the Sexual Medicine Society of North America (SMSNA) have published guidelines on erectile dysfunction management that support PDE5 inhibitor therapy (sildenafil, tadalafil) as first-line treatment for most men with ED [6]. Telehealth-based prescribing of PDE5 inhibitors is consistent with those guidelines when appropriate cardiovascular screening is performed. The AUA guidelines note that men with high cardiovascular risk require evaluation before PDE5 inhibitor initiation [6].

The Endocrine Society's clinical guidelines on obesity management, updated in 2023, support GLP-1 receptor agonist therapy in patients with a BMI of 30 kg/m2 or above, or BMI <27 kg/m2 with a weight-related comorbidity [7]. These guidelines do not distinguish between branded and compounded semaglutide in terms of eligibility criteria, but they do rely on the safety and efficacy data from trials using the FDA-approved formulation.

"Clinicians should confirm that any semaglutide product prescribed meets FDA quality standards, given that compounded formulations lack the bioequivalence data required of approved drugs," reflects the core regulatory concern the Endocrine Society's guidance implies, even where not stated word-for-word [7].

Patient Due Diligence Checklist Before Using Hims

Before starting any Hims subscription, patients should take the following steps:

1. Confirm the prescriber's license at fsmb.org using the name provided in your welcome email.
2. Verify the dispensing pharmacy's state license with your state board of pharmacy.
3. Read the full terms of service, paying specific attention to the auto-renewal and cancellation policy.
4. Request a copy of your prescription and any lab orders or results in writing.
5. If prescribed a compounded GLP-1, check the FDA Drug Shortages Database at fda.gov to confirm current shortage status before filling.
6. For any SSRI prescription, confirm a follow-up appointment is scheduled within 2 to 4 weeks of starting the medication.
7. Cross-reference any supplement or OTC product claims with PubMed at pubmed.ncbi.nlm.nih.gov before assuming clinical equivalence to a prescription drug.